Suppr超能文献

针对多个病毒靶点的丙型肝炎病毒复制小分子抑制剂的协同作用。

Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.

作者信息

Wyles David L, Kaihara Kelly A, Vaida Florin, Schooley Robert T

机构信息

Department of Medicine, Divivion of Infectious Diseases, University of California-San Diego, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA.

出版信息

J Virol. 2007 Mar;81(6):3005-8. doi: 10.1128/JVI.02083-06. Epub 2006 Dec 20.

Abstract

Chronic hepatitis C virus (HCV) infection is a significant worldwide health problem with limited therapeutic options. A number of novel, small molecular inhibitors of HCV replication are now entering early clinical trials in humans. Resistance to small molecular inhibitors is likely to be a significant hurdle to their use in patients. A systematic assessment of combinations of interferon and/or novel anti-hepatitis C virus agents from several different mechanistic classes was performed in vitro. Combinations of inhibitors with different mechanisms of action consistently demonstrated more synergy than did compounds with similar mechanisms of action. These results suggest that combinations of inhibitors with different mechanisms of action should be prioritized for assessment in clinical trials for chronic hepatitis C virus infection.

摘要

慢性丙型肝炎病毒(HCV)感染是一个全球性的重大健康问题,治疗选择有限。目前,一些新型的HCV复制小分子抑制剂正进入人体早期临床试验阶段。小分子抑制剂的耐药性可能是其在患者中应用的重大障碍。我们在体外对来自几种不同作用机制类别的干扰素和/或新型抗丙型肝炎病毒药物的组合进行了系统评估。与具有相似作用机制的化合物相比,具有不同作用机制的抑制剂组合始终表现出更强的协同作用。这些结果表明,在慢性丙型肝炎病毒感染的临床试验评估中,应优先考虑具有不同作用机制的抑制剂组合。

相似文献

1
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.
J Virol. 2007 Mar;81(6):3005-8. doi: 10.1128/JVI.02083-06. Epub 2006 Dec 20.
2
Selective inhibitors of hepatitis C virus replication.
Antiviral Res. 2006 Sep;71(2-3):363-71. doi: 10.1016/j.antiviral.2006.06.006. Epub 2006 Jun 23.
3
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
Antimicrob Agents Chemother. 2006 May;50(5):1813-22. doi: 10.1128/AAC.50.5.1813-1822.2006.
4
Hepatitis C virus resistance to protease inhibitors.
J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1.
5
Inhibition of hepatitis C virus replication by antimonial compounds.
Antimicrob Agents Chemother. 2005 Oct;49(10):4197-202. doi: 10.1128/AAC.49.10.4197-4202.2005.
6
Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Antiviral Res. 2015 Jan;113:93-102. doi: 10.1016/j.antiviral.2014.10.017. Epub 2014 Nov 20.
10
Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.
J Viral Hepat. 2009 Jul;16(7):506-12. doi: 10.1111/j.1365-2893.2009.01102.x. Epub 2009 Mar 3.

引用本文的文献

1
Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir.
Biochem Biophys Rep. 2022 May 24;30:101283. doi: 10.1016/j.bbrep.2022.101283. eCollection 2022 Jul.
2
Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant.
ACS Omega. 2019 Oct 2;4(16):16999-17008. doi: 10.1021/acsomega.9b02491. eCollection 2019 Oct 15.
3
Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.
PLoS One. 2017 Nov 15;12(11):e0187857. doi: 10.1371/journal.pone.0187857. eCollection 2017.
4
Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression.
J Virol Antivir Res. 2014 Oct 6;3(3). doi: 10.4172/2324-8955.1000129.
5
Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease.
Antiviral Res. 2015 Dec;124:54-60. doi: 10.1016/j.antiviral.2015.10.001. Epub 2015 Nov 9.
6
Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes.
CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):445-53. doi: 10.1002/psp4.12005. Epub 2015 Jul 6.
7
Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro.
Antiviral Res. 2015 Mar;115:39-47. doi: 10.1016/j.antiviral.2014.12.018. Epub 2014 Dec 31.
8
Functional conservation despite structural divergence in ligand-responsive RNA switches.
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15952-7. doi: 10.1073/pnas.1414678111. Epub 2014 Oct 27.
10
An in vitro synergistic interaction of combinations of Thymus glabrescens essential oil and its main constituents with chloramphenicol.
ScientificWorldJournal. 2014 Jan 28;2014:826219. doi: 10.1155/2014/826219. eCollection 2014.

本文引用的文献

1
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.
Ann Intern Med. 2006 May 16;144(10):705-14. doi: 10.7326/0003-4819-144-10-200605160-00004.
2
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
Antimicrob Agents Chemother. 2006 May;50(5):1813-22. doi: 10.1128/AAC.50.5.1813-1822.2006.
5
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
J Biol Chem. 2005 Nov 4;280(44):36784-91. doi: 10.1074/jbc.M506462200. Epub 2005 Aug 8.
7
Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.
J Med Chem. 2004 Dec 16;47(26):6603-8. doi: 10.1021/jm0401255.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验